Clinical trials: Zoledronic Acid
Breast Neoplasms
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
This study will evaluate the safety/efficacy of zoledronic acid when given by intravenous infusion every 4 weeks in addition to letrozole as endocrine therapy in postmenopausal patients with hormone responsive breast cancer
- Trial name
- FEMZONE (NCT00375752)
- Testing
- Letrozole, Zolendronic Acid
- Where
- 27 sites in Germany
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
This study is being conducted to evaluate the effect of an investigational drug on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT).
- Trial name
- NCT00171639
- Testing
- zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Postmenopausal Women
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women.
- Trial name
- NCT01721993
- Testing
- T121, Zoledronic acid
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Thar Pharmaceuticals, Inc
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
- Trial name
- NCT00247650
- Testing
- Zoledronic Acid; Letrozole
- Where
- 10 sites in Canada
- Volunteers
- 190 people
- Sponsor
- Novartis
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of Bone
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).
- Trial name
- NCT00774020
- Testing
- Zoledronic acid
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Cancer, Neoplasm Metastasis
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
- Trial name
- NCT00172003
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.
- Trial name
- NCT00242528
- Testing
- Zoledronic acid
- Sponsor
- Novartis
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Bone Metastatic Non-small Cell Lung Cancer
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of…
- Trial name
- NCT04325776
- Testing
- AL2846, Zoledronic Acid Injection
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Osteoporosis
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
The purpose of this trial is to study the clinical safety, tolerability, and efficacy of zoledronic acid compared to an oral bisphosphonate in postmenopausal women with osteoporosis.
- Trial name
- NCT00100555
- Testing
- zoledronic acid
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.
- Trial name
- NCT00097812
- Testing
- zoledronic acid
- Where
- 13 sites in United States, Germany
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Multiple Myeloma
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion.
- Conditions
- Breast Cancer, Multiple Myeloma, Prostate Cancer
- Trial name
- NCT00029224
- Testing
- zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Novartis
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099203
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 72 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099177
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis
Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
This study is to compare the two medications Denosumab and Zoledronic Acid For Patients With Beta Thalassemia Major Induced Osteoporosis.
- Trial name
- DOHA (NCT03040765)
- Testing
- Denosumab 60 MG/ML Prefilled Syringe, Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- Qatar
- Volunteers
- 17 people
- Sponsor
- Hamad Medical Corporation
Prostate Cancer
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC)…
- Trial name
- NCT00072930
- Testing
- MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
- Where
- 57 sites in United States, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- MedImmune LLC